Immuron reduces liver inflammation

Immuron Limited (ASX: IMC) said results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study were positive. Results demonstrate excellent safety and tolerability; statistically significant reduction in serum endotoxin/liposaccharid

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.